Swine | boehringer-ingelheim.com

Livestock

More than 45 per cent of Boehringer Ingelheim Animal Health Business Unit’s global revenue comes from our livestock business (poultry, ruminant, swine and Veterinary Public Health), driven by innovative parasiticides, vaccines and therapeutics, as well as our history of partnership with livestock producers, livestock veterinarians, government officials and NGOs.

We bring innovative health solutions to our customers to prevent disease in livestock. In doing so, we help livestock producers produce more high quality food using fewer natural resources.

We also strive to address some of the most pressing challenges facing our livestock customers, such as the need to cost-effectively produce more protein to feed the world's growing population. By 2050, the global population will reach 9.7 billion people, with a significant increase in the middle class, and substantial growth in emerging markets like Africa and Asia. As a result, the demand for animal protein is expected to increase by 70 per cent. 

In response to a growing public health concern over antibiotic resistance and the need for food safety, we focus on developing solutions that prevent or reduce the need for antibiotics while at the same time improving the quality and safety of our food.

We are here to help our customers tackle these challenges with preventive care solutions. Furthermore, we are increasing our focus on non-traditional animal health offerings, such as point-of-care diagnostic technologies, live biotherapeutics, and digital solutions.


Swine 

Boehringer Ingelheim is a partner and enabler of sustainable pork and animal protein production, ensuring animal welfare through prevention and integrated health care. We keep innovating to respond to, meet and exceed our customers’ needs and provide new value added digital solutions that prevent disease thus increasing performance and productivity of animals.

Our holistic solutions under the ‘Prevention Works’ umbrella enable us to offer our customers integrated health tools and experience which subsequently lead to improved animal well-being, better economic performance, less waste, better use of resources and sustainable production of healthy and good quality food.

We invest into our own R&D and form partnerships with companies and institutes to continuously bring innovate solutions to the market. One of the examples is our support of African swine fever control by providing biosecurity and diagnostics & monitoring tools and collaborating on the development of vaccines with world-class institutes and reference labs, such as the Pirbright Institute (UK), Friedrich Loeffler Institute (Germany) and Harbin Institute (China).